Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Drug Reactions01:27

Allergic Drug Reactions

1.1K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.1K
Pharmacovigilance01:19

Pharmacovigilance

1.3K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.3K
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

2.7K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.7K
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

98
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
98
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.4K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.4K
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

143
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
143

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mouse model of Staphylococcus aureus- and Pseudomonas aeruginosa-induced neutrophilic chronic rhinosinusitis.

Rhinology·2025
Same author

Validation and shortcomings of the most common mouse model of chronic rhinosinusitis with nasal polyps.

Rhinology·2024
Same author

[Potential therapeutic implication of focal adhesion kinase in small-cell lung cancer].

Revue des maladies respiratoires·2023
Same author

[Severe intraocular inflammation after surgery for unilateral posterior lenticonus, resolving on topical steroids].

Journal francais d'ophtalmologie·2021
Same author

[Immunotherapy for head and neck squamous cell carcinoma].

Revue medicale de Liege·2021
Same author

[Glioblastoma].

Revue medicale de Liege·2021

Related Experiment Video

Updated: Nov 3, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.6K

[Immune-related adverse events].

P Frères1, A Poncin1, M Lecocq1

  • 1Service d'Oncologie médicale, CHU Liège, Belgique.

Revue Medicale De Liege
|June 3, 2021
PubMed
Summary

Cancer immunotherapy is transforming patient care. Understanding and managing its specific immune-related side effects early is crucial for effective treatment.

Area of Science:

  • Oncology
  • Immunology
  • Clinical Medicine

Background:

  • Cancer immunotherapy has emerged as a revolutionary treatment modality.
  • Its application is expanding, impacting a growing number of cancer patients.
  • Immune-related adverse events are a significant clinical consideration.

Purpose of the Study:

  • To outline the primary adverse effects associated with cancer immunotherapy.
  • To provide general principles for the management of these immune-related side effects.
  • To emphasize the importance of early recognition and intervention.

Main Methods:

  • Review of current literature on immunotherapy adverse events.
  • Synthesis of established management strategies for immune-related side effects.
Keywords:
ImmuneImmunotherapyToxicityCancerrelated adverse events

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.7K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.0K

Related Experiment Videos

Last Updated: Nov 3, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.6K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.7K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.0K
  • Clinical guidance based on expert consensus.

    • Main Results:

    • Adverse effects of immunotherapy are characteristically immune-related.
    • Specific organ systems can be affected by these immune-related toxicities.
    • Timely diagnosis and appropriate management are key to patient outcomes.

    Conclusions:

    • Effective management of immunotherapy requires a thorough understanding of its side effect profile.
    • Early identification and prompt treatment of immune-related adverse events are essential.
    • Adherence to management principles can mitigate treatment complications and improve patient safety.